Longevity Goes Middle Class
Marco@marco
The idea
I believe longevity medicine follows the same path as weight-loss drugs: expensive and exclusive at first, then cheap enough for the middle class within 5 to 10 years. This basket splits evenly between companies already selling longevity at scale, like weight-loss drugmakers and glucose sensor makers, and the next wave likely to follow that same price curve, including blood testing, early cancer screening, wearables, and clinics that sell to wealthy people first.
What it owns
- These drugs are the first longevity products already moving from expensive to mass market, anchoring the take. · Eli LillyIt makes the first oral GLP-1 weight-loss drug at prices that bring these treatments into reach for ordinary households., Novo NordiskIt makes an oral weight-loss drug competing at mass-market prices, the second company pushing these treatments toward affordability., AmgenIt is building its own obesity drug, adding a third major company that could push prices further down through competition., AstraZenecaIt is working on weight-loss pills, adding more competitors whose growth pushes prices toward what middle-class families can afford., Viking TherapeuticsIt is a small company betting almost everything on an obesity drug, offering big upside if the drug competes or big drops if it doesn't.32%
- Blood tests and early cancer screens are mostly paid out of pocket today and get much bigger if insurers start covering them. · GRAILIt sells a multi-cancer blood test mostly paid for out of pocket today, at the rich-first stage of longevity adoption., NateraIt runs DNA blood tests including cancer recurrence monitoring, moving from specialty care toward routine coverage., Quest DiagnosticsIt sells blood tests directly to consumers so people can order health panels without a doctor's visit., Guardant HealthIt sells a blood test for colon cancer screening that could reach far more people as a simpler alternative to colonoscopy., IlluminaIt makes machines behind much of the world's DNA testing, supplying the same price curve that drives longevity toward mass market., LabcorpIt is one of the two giant US lab networks turning its infrastructure into tests that regular people buy for themselves.25%
- Glucose sensors are moving from diabetics to healthy people who want to track their bodies, sold by companies that can manufacture them cheaply in huge volumes. · Abbott LaboratoriesIt makes the Libre glucose sensor at scale and sells a consumer version straight to people without diabetes., DexcomIt sells an over-the-counter glucose sensor that turns a diabetes device into a wellness product for ordinary people.15%
- These companies sell longevity to people paying cash first, then grow as prices come down. · Hims & Hers HealthIt runs an online clinic where people pay cash for weight-loss drugs and other treatments, a main channel for affordable longevity care., Life Time GroupIt runs premium gyms and added longevity clinic services sold to members first, opening the wealthy-first stage of the take.11%
- Tracking health every day needs devices and software that turn the readings into something useful. · GarminIt makes watches that track heart rate, sleep and fitness at prices middle-class buyers already pay, longevity tracking gone mainstream., Tempus AIIt combines genetic testing with AI to make sense of health data, work that gets cheaper as it scales.9%
- Cash8%